Specderm Poznanska Sp. j.

Bialystok 25 trials 10 recruiting

25 Registered trials

10 Currently recruiting

Organisation

Specderm Poznanska Sp. j.

Location

Bialystok, Poland

Identifier

ORG-100046187

Address

Ul. Prezydenta Ryszarda Kaczorowskiego 7/u 50, 15-375, Poland

Departments

40626: Dermatology
40626: NAP
Dermatology
n/a
NA
No Department
Not Applicable
SPECDERM
Specderm Poznanska
SPECDERM Poznanska sp.j

Clinical trials at this site (25)

Search interface

Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri… Recruiting

2025-523404-74-00 Prurigo Nodularis 4 2026-05-26
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting

2024-520337-80-00 Palmoplantar Pustulosis 5 2026-01-07
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Pso… Recruiting

2024-515706-77-00 Moderate to Severe Plaque Psoriasis 5 2025-05-08
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
A Phase 2a double blind, randomized, parallel arm, placebo-controlled trial to investigate the effects of two dose levels of CIT-013 on dise… Recruiting

2025-521684-12-00 Hidradenitis Suppurativa 4 2026-01-13
A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder… Recruiting

2023-506296-97-00 Moderate to Severe Plaque Psoriasis 5 2025-10-28
Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and pla… Recruiting

2023-510338-10-00 Recurrent herpes labialis (RHL) 5 2025-01-15
A Study of the Efficacy and Safety of JNJ-77242113 in Biologic-naïve Participants with Active Psoriatic Arthritis Ended

2023-509239-19-00 Active Psoriatic Arthritis 5 2025-04-03
A Clinical Study in which patients with acne vulgaris will receive a new topical drug. The safety and efficacy of the drug will be tested. Ended

2023-510341-19-00 acne vulgaris 5 2024-11-14
A Clinical Study in which patients with acne vulgaris will receive a new topical drug for long term. The safety and efficacy of the drug wil… Ended

2023-510342-24-00 Acne vulgaris 5 2024-11-11
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended

2022-502518-98-00 nonsegmental vitiligo 5 2024-04-26
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505120-59-00 Moderate to Severe Plaque Psoriasis 5 2023-12-19
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm… Ended

2023-505122-34-00 Plaque Psoriasis 5 2023-12-05
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A clinical trial to evaluate safety, efficacy, and tolerability of abrocitinib in subjects with chronic hand eczema. Ended

2023-504539-42-00 Moderate to severe chronic hand eczema 4 2024-10-20
Evaluation of efficacy and safety of 0.1% mometasone furoate cutaneous emulsion compared to its active ingredient-free base and a comparator… Ended

2024-511583-82-00 Plaque psoriasis 5 2024-10-08
A research study comparing how well different doses of the medicine NNC0487-0111 lower blood sugar in people with type 2 diabetes Ended

2023-509412-28-00 Type 2 Diabetes 4 2024-07-26
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control W… Ended

2023-507206-13-00 Type 2 Diabetes 5 2024-03-14
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended

2022-503062-72-00 Chronic Spontaneous Urticaria 4 2023-11-23
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis Ended

2022-502888-38-00 Atopic dermatitis 4 2023-09-25